ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.760,22
0,16%
S&P 500
5.418,17
-0,29%
US Dollar vs BRL
5,3573
-0,11%
Bitcoin
66.399,99
-0,53%
Brent Oil
82,505
0,65%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. LumiraDx Ltd (LMDX)

  7. LumiraDx Ltd (LMDX) Notícias

LMDX

LumiraDx (LMDX)

LumiraDx Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:LMDX
DataHoraFonteTítuloCódigoCompanhia
05/01/202419:45GlobeNewswire Inc.LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9thNASDAQ:LMDXLumiraDx Ltd
29/12/202319:07Dow Jones NewsLumiraDx Agrees to Sell Point-of-Care Tech Platform to RocheNASDAQ:LMDXLumiraDx Ltd
29/12/202318:15GlobeNewswire Inc.LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to RocheNASDAQ:LMDXLumiraDx Ltd
27/10/202317:45GlobeNewswire Inc.LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to AppealNASDAQ:LMDXLumiraDx Ltd
20/10/202319:34GlobeNewswire Inc.LumiraDx Partners with AstraZeneca & Everton in the Community to Set Up England’s First Heart & Lung Screening HubNASDAQ:LMDXLumiraDx Ltd
24/08/202308:45GlobeNewswire Inc.LumiraDx Reports Second Quarter 2023 ResultsNASDAQ:LMDXLumiraDx Ltd
16/08/202317:30GlobeNewswire Inc.LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24NASDAQ:LMDXLumiraDx Ltd
31/07/202307:00GlobeNewswire Inc.LumiraDx’s Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and TestsNASDAQ:LMDXLumiraDx Ltd
30/06/202316:26Dow Jones NewsLumiraDx Submits Dual FDA Medical Device Application for Covid-19 TestNASDAQ:LMDXLumiraDx Ltd
30/06/202315:30GlobeNewswire Inc.LumiraDx Submits First 510(k) Application to the FDA for COVID Ultra TestNASDAQ:LMDXLumiraDx Ltd
20/06/202317:15GlobeNewswire Inc.LumiraDx Receives UK CTDA Approval for COVID Ultra and COVID & RSV TestsNASDAQ:LMDXLumiraDx Ltd
16/05/202308:45GlobeNewswire Inc.LumiraDx Reports First Quarter 2023 ResultsNASDAQ:LMDXLumiraDx Ltd
09/05/202317:15GlobeNewswire Inc.LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 16NASDAQ:LMDXLumiraDx Ltd
24/04/202317:21GlobeNewswire Inc.LumiraDx Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:LMDXLumiraDx Ltd
06/04/202310:20GlobeNewswire Inc.LumiraDx Announces Strategic Refocus and Cost Restructuring ProgramNASDAQ:LMDXLumiraDx Ltd
21/03/202308:26GlobeNewswire Inc.LumiraDx Reports Fourth Quarter and Full Year 2022 ResultsNASDAQ:LMDXLumiraDx Ltd
14/03/202309:03GlobeNewswire Inc.LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21NASDAQ:LMDXLumiraDx Ltd
03/03/202311:00GlobeNewswire Inc.LumiraDx to Present at Raymond James Institutional Investors ConferenceNASDAQ:LMDXLumiraDx Ltd
20/02/202313:00GlobeNewswire Inc.LumiraDx Regains Compliance with Nasdaq Continued Listing RequirementsNASDAQ:LMDXLumiraDx Ltd
06/02/202310:59Dow Jones NewsLumiraDx Gets FDA Emergency Authorization for Dual Flu-COVID TestNASDAQ:LMDXLumiraDx Ltd
06/02/202310:00GlobeNewswire Inc.LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular AssayNASDAQ:LMDXLumiraDx Ltd
31/01/202318:30GlobeNewswire Inc.LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UKNASDAQ:LMDXLumiraDx Ltd
31/01/202318:15GlobeNewswire Inc.LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price DeficiencyNASDAQ:LMDXLumiraDx Ltd
14/12/202205:19GlobeNewswire Inc.LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis TestNASDAQ:LMDXLumiraDx Ltd
08/12/202205:01GlobeNewswire Inc.Latest Clinicians’ U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing CentersNASDAQ:LMDXLumiraDx Ltd
14/11/202211:44PR Newswire (US)LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c TestNASDAQ:LMDXLumiraDx Ltd
14/11/202201:05TipRanksLumiraDx (LMDX) Gets a Buy from BTIGNASDAQ:LMDXLumiraDx Ltd
11/11/202209:35TipRanksRaymond James Remains a Buy on LumiraDx (LMDX)NASDAQ:LMDXLumiraDx Ltd
09/11/202209:00GlobeNewswire Inc.LumiraDx Reports Third Quarter 2022 ResultsNASDAQ:LMDXLumiraDx Ltd
02/11/202208:23GlobeNewswire Inc.LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9NASDAQ:LMDXLumiraDx Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:LMDX

Seu Histórico Recente

OKEX
BECBTC
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados